Modality
ASO
MOA
PLK4i
Target
TYK2
Pathway
Checkpoint
SMAMigraineCSU
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Mar 2030
Phase 1Current
NCT03975615
1,798 pts·CSU
2022-12→2025-07·Not yet recruiting
NCT03522058
1,676 pts·Migraine
2020-10→2030-03·Not yet recruiting
3,474 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-139mo agoInterim· CSU
2030-03-254.0y awayInterim· Migraine
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Not yet…
P1
Not yet…
Catalysts
Interim
2025-07-13 · 9mo ago
CSU
Interim
2030-03-25 · 4.0y away
Migraine
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03975615 | Phase 1 | CSU | Not yet recr... | 1798 | UPCR |
| NCT03522058 | Phase 1 | Migraine | Not yet recr... | 1676 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 | |
| RAR-1117 | Ultragenyx | Phase 1/2 | TYK2 | |
| Datocilimab | Neumora | Phase 1 | TYK2 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| Polaglumide | Foghorn | Phase 3 | TYK2 |